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Here we present the hypothesis that increasing copy number (dosage) of sequences
encoding DUF1220 protein domains is a major contributor to the evolutionary increase
in brain size, neuron number, and cognitive capacity that is associated with the primate
order. We further propose that this relationship is restricted to the anthropoid sub-order
of primates, with DUF1220 copy number markedly increasing in monkeys, further in apes,
and most extremely in humans where the greatest number of copies (∼272 haploid
copies) is found. We show that this increase closely parallels the increase in brain
size and neuron number that has occurred among anthropoid primate species. We also
provide evidence linking DUF1220 copy number to brain size within the human species,
both in normal populations and in individuals associated with brain size pathologies
(1q21-associated microcephaly and macrocephaly). While we believe these and other
findings presented here strongly suggest increase in DUF1220 copy number is a key
contributor to anthropoid brain expansion, the data currently available rely largely on
correlative measures that, though considerable, do not yet provide direct evidence for
a causal connection. Nevertheless, we believe the evidence presented is sufficient to
provide the basis for a testable model which proposes that DUF1220 protein domain
dosage increase is a main contributor to the increase in brain size and neuron number
found among the anthropoid primate species and that is at its most extreme in human.
Keywords: DUF1220, protein domain, copy number, human brain expansion, gene duplication and evolution, gene
dosage, anthropoid brain evolution
HYPOTHESIS: ANTHROPOID PRIMATE BRAIN EXPANSION IS
PRIMARILY DRIVEN BY DUF1220 DOMAIN DOSAGE
Here we provide an overview of the data supporting the view that
DUF1220 copy number (dosage) increase is a major contributor
to the increase in neuron number, brain size, and cognitive ability
that has occurred specifically in the anthropoid sub-order (mon-
keys, apes, humans) of primates, including the evolutionarily
rapid and extreme expansion of the human brain.
EXPANSION OF THE PRIMATE BRAIN HAS OCCURRED VIA AN
EVOLUTIONARY MECHANISM UNIQUE TO PRIMATES
Recent studies have indicated that, among primates, brain expan-
sion has been driven by unique neuronal scaling rules such that
larger brains can be accounted for primarily by gains in neuron
number, unlike any other lineage so far investigated (Herculano-
Houzel et al., 2007). Although this trend has not yet been inves-
tigated in lineages that contain large brained animals such as
pachyderms and cetaceans, this phenomenon may help to explain
differences between the cognitive abilities of humans and other
large brained animals, such as elephants, whales, and dolphins.
This is a significant finding that has a number of important impli-
cations. First, it indicates that cell size in the mammalian brain is
not a fixed value, and secondly that neuron number across species
must therefore be evaluated independently of brain size.
As has recently been reported, neuronal scaling, and density
appear to vary by taxonomic order, with primate brain evolu-
tion taking its own unique path (Herculano-Houzel, 2009). It has
been pointed out that body size might not be a relevant parameter
for defining a species’ behavioral performance. Rather, absolute
numbers of brain neurons might be a much more important
factor. This idea is based on the finding that a larger body size
between two rodents of different species seems to be accompa-
nied by an increase in brain size due in large part to an increase
in neuron size, and therefore a reduction in neuron density
(Herculano-Houzel et al., 2006). In primates, on the other hand,
neuron size and density stay nearly the same. Cell number there-
fore accounts for a much larger proportion of the difference in
brain mass between primates as compared to the differences in
brain mass between rodent brains. This shift in emphasis from
cell mass to cell number seems to be unique to the primates as an
order, rather than humans alone, suggesting that primate brain
expansion has proceeded by a different mechanism than that used
by non-primates.
Mechanistically, this model also makes intuitive sense. Because
neurons are fundamentally on/off switches, there is no intrinsic
advantage for an animal to have larger neurons. Indeed, the extra
energy required to maintain larger cells in a larger animal that
are performing the same function may instead be a disadvantage,
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offset only by the advantage provided by a larger overall body
size.
By contrast, there is a distinct advantage in processing power
in an animal that is able to keep neuron size to a mini-
mum and instead increase neuron number. Additionally, neurons
can be considered the fundamental units of cognitive power.
Having more neurons likely produces higher cognitive function
by expanding the processing capacity of input, processing, and
association regions. This should in theory allow an animal to
have added layers of pattern recognition and connect increasingly
more complex outputs, and therefore be capable of producing
more complex thought patterns. Because primates tend to have
more neurons than non-primates of equal brain size, this pro-
vides a plausible explanation for the observed greater cognitive
capacity of primates when compared to non-primate mammals.
Taken together these findings support the view that among
mammalian species, brain evolution in primates has occurred by
a different mechanism. Namely, that the increase in brain size and
cognitive ability found among primates, and particularly humans,
has been primarily due to an increase in neuron number.
DUF1220 PROTEIN DOMAIN COPY NUMBER INCREASE SHOWS A
PRIMATE-SPECIFIC BURST THAT CLOSELY PARALLELS BRAIN SIZE
AND NEURON NUMBER AMONG PRIMATE SPECIES
The highest number of DUF1220 copies is found in the human
lineage
It has been well-established that extreme gene duplication in a
species-specific manner can be a key contributor to the evolution
of phenotypic traits unique to that species. In order to identify
such extreme duplication events, we previously used genome-
wide and gene-based arrayCGH to identify lineage-specific gene
copy number changes among primate species including human
(Fortna et al., 2004). This study surveyed essentially all human
genes (e.g., approximately 24,000) and identified 1,004 that
showed lineage-specific copy number changes among humans
and the 4 great ape species. Of 140 genes identified that showed
human lineage-specific (HLS) gain or loss in copy number, the
most extreme change was found to be due to sequences encoding
DUF1220, a protein domain of unknown function (Popesco et al.,
2006). DUF1220 domains are on average approximately 65 amino
acids in size, are found almost exclusively within the NBPF gene
family (Vandepoele et al., 2005) and are located primarily in the
1q21.1 region of chromosome 1.
There are many more copies of DUF1220 encoded in the
human genome compared to the genome of any other species
(Table 1). Humans have approximately 270 haploid copies, far
more than great apes (90–125 copies), monkeys (25–40 copies),
and especially prosimians and non-primate mammals (1–9
copies) (O’Bleness et al., 2012a). Indeed, DUF1220 shows the
largest HLS increase in copy number of any protein coding
sequence in the human genome (O’Bleness et al., 2012b).
It is worth noting that these increases occur in the DNA
sequences of a gene coding region and specifically in a protein
domain, characteristics that make them much more likely to be
functionally and phenotypically important. Their potential sig-
nificance is further supported by molecular evolutionary analyses
of DUF1220 coding sequences which show that DUF1220
Table 1 | DUF1220 Copy Number in 41 Animal Genomes.
Genome PDE4DIP Total NBPF
DUF1220 Genes
EUARCHOTANGLIRES
Anthropoids Human 2 272 23
Chimp 3 125 19
Gorilla 3 99 15
Orangutan 4 92 11
Gibbon 3 53 10
Macaque 1 35 10
Marmoset 1 31 11
Prosimians Mouse Lemur 1 2 1
Bushbaby 1 3 2
Tarsier 1 1 0
Rabbit 1 8 3
Pika 1 1 0
Mouse 1 1 0
Rat 1 1 0
Guinea Pig 1 1 1
Squirrel 1 1 1
Tree Shrew 1 4 3
LAURASIATHERIA
Cow 1 7 3
Dolphin 1 4 1
Pig 1 3 1
Horse 1 8 3
Dog 1 3 1
Panda 1 2 1
Cat 1 3 2
Megabat 1 1 0
Microbat 1 1 0
Hedgehog 1 1 0
Shrew 1 1 0
XENARTHRA
Armadillo 1 1 0
Sloth 1 1 0
AFROTHERIA
Elephant 1 1 2
Hyrax 1 1 0
Tenrec 1 1 0
METATHERIA
Opossum 1 1 0
Wallaby 1 1 0
PROTOTHERIA
Platypus 1 1 0
OTHER VERTEBRATE
Chicken 0 0 0
Zebra Finch 0 0 0
Lizard 0 0 0
Frog 0 0 0
Zebrafish 0 0 0
DUF1220 copy number was estimated using BLAT searches of 41 available ani-
mal genomes as described in O’Bleness et al. (2012a). PDE4DIP refers to the
copy number of the ancestral form of DUF1220, which is found only in the
PDE4DIP gene. Also listed is the copy number of the NBPF genes, i.e., those
containing the derived form of DUF1220 and that expanded particularly in the
anthropoid species.
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domains have undergone strong positive selection especially
among primates (Popesco et al., 2006).
DUF1220 increase in humans is primarily due to hyper-amplification
of the DUF1220 triplet
We have estimated that approximately 160 copies of DUF1220
were added specifically to the human genome since theHomo/Pan
lineages diverged from one another approximately 5–6 million
years ago. This extraordinary expansion corresponds to an aver-
age of ∼28 copies added specifically to the human genome every
million years since this split. However, phylogenetic analyses of
the new HLS copies suggests that this expansion did not fol-
low a constant rate of increase, and particularly large bursts of
DUF1220 copy number likely occurred in very recent human evo-
lution (e.g., within the last 1–2 million years) (O’Bleness et al.,
2012a).
It is noteworthy that the most extreme HLS increase in
DUF1220 copy number involves intra-genic domain amplifica-
tion, rather than gene duplication. DUF1220 protein domains can
be divided into six clades based on sequence similarity: Conserved
clades 1, 2, and 3 (CON1-3) and Human Lineage Specific clades
1, 2, and 3 (HLS1-3). The clades exhibit specific positions within
NBPF genes, with CON1, and CON2 being the N-terminal-most
domains followed by the three HLS clades with CON3 being the
C-terminal-most domain (O’Bleness et al., 2012a). Interestingly,
the three HLS DUF1220 clades combine to make up a repeating
unit comprised of three HLS DUF1220 domains (HLS1, HLS2,
HLS3) that we have named the HLS DUF1220 triplet. The HLS
expansion of this triplet represents one of the most extreme,
rapid, and recent copy number expansions found in the human
genome (O’Bleness et al., 2012b). We estimate that remark-
ably 148 of the 160 DUF1220 copies added specifically to the
human lineage since the Homo/Pan split were due to intragenic
hyper-amplification of the HLS DUF1220 triplet.
A phylogenetic profile of DUF1220 expansion in the human
lineage shows that, because the triplets are so similar, it is likely
the majority were generated very recently in human evolution,
perhaps within the past 500,000 years (O’Bleness et al., 2012a).
More precise estimation of when the DUF1220 triplet hyper-
amplification occurred should be obtained as more complete and
accurate genome sequences become available from evolutionarily
recent human relatives, e.g., Neanderthals, Denisovans.
Finally, the data presented strongly suggests that this excep-
tional DUF1220 copy number increase has conferred a consider-
able evolutionary advantage to anthropoid primates, first among
monkeys, then apes, and most recently and extremely among
humans.
DUF1220 copy number shows a strong correlation with brain size,
neuron number, and other cognitive phenotypes among primates
When compared across primates, DUF1220 copy number
shows a remarkably close correlation with cortical neu-
ron number (R2 = 0.98; p = 1.1 × 10−3) and brain size
(R2 = 0.98; p = 1.8 × 10−6) (Dumas et al., 2012). Further
examination of brain measurements in 131 individuals from 7
Catarrhini species (Old worldmonkeys, apes, and humans), made
using MRI, reveals significant correlations between DUF1220
domain dosage and increases in gray matter (p = 1.3 × 10−4),
surface area (p = 7.8 × 10−5), gyrification (p = 2.0 × 10−3) and
white matter (p = 2.1 × 10−5) (Keeney et al., in press). However,
no significant correlation is found when DUF1220 copy number
is compared to primate body size.
While there has been an unusually large and rapid increase in
brain size specifically in humans, this is part of a process that
has a long evolutionary history. Several neurobiological trends,
such as an expanded neocortex in humans, are an extension of an
evolutionary direction already begun in the brains of other pri-
mates that was evident well before the human lineage diverged
from the Pan lineage (chimp and bonobo). It is estimated that
30–40 Mya neocortical portions of the brain increased in the
two emerging anthropoid lineages (platyrrhines and catarrhines)
and 8–16Mya another enlargement occurred in the lineage to
the modern hominids (Goodman, 1999; Sikela, 2006). Still, the
largest neocortical increase is thought to have occurred over the
past 3 million years in the human lineage.
This continued progressive increase in primate brain size over
60 million of years of evolution shows a strikingly close paral-
lel with the sustained and stepwise copy number expansion of
DUF1220 domains among these species. As mentioned above,
the most extreme DUF1220 copy number expansions are those
that are restricted to the human species and are likely to have
occurred via small and large incremental increases. Thus, while
the strategy of producing more neurons to facilitate brain expan-
sion is restricted to the anthropoid primate sub-order, so too is
the extraordinary evolutionary burst in DUF1220 copy number.
While these findings are consistent with DUF1220 dosage playing
a significant role in anthropoid brain expansion, the supportive
data are at present correlative. Additional studies are underway
that more directly test the involvement of DUF1220 dosage in
brain size and neuron number (see Author Note).
DUF1220 protein domain copy number in Neanderthals
It has been long established that Neanderthals are thought to have
had, on average, a larger brain than modern humans (Holloway,
1985) and recent genome sequence analysis of Neanderthals indi-
cates that they also have more DUF1220 copies (∼350) than
modern humans (∼270) (Dumas et al., 2012; O’Bleness et al.,
2012a). This lends further support to the view that DUF1220
dosage is associated with brain size increase among all primate
species studied, including humans and Neanderthals.
However, the fact that Neanderthals show the greatest num-
ber of DUF1220 copies among all mammals raises a number of
questions: First, because of the imprecise nature of the available
Neanderthal sequence we do not currently know which types of
DUF1220 copies are found in the Neanderthal genome. As men-
tioned above (section DUF1220 Increase in Humans is Primarily
due to Hyper-Amplification of the DUF1220 Triplet), in humans
DUF1220 domains are found in six similar clades that are orga-
nized in a specific order within the NBPF genes that encode
them. While some clades have been more strongly implicated in
brain-size related phenotypes, the exact functions of the differ-
ent clades are not known. Secondly, we do not know the cause of
the Neanderthal extinction, and therefore we cannot make con-
clusions about whether brain function and/or cognitive capacity
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played a role in this process. There are several theories that pro-
pose different types of causes for the Neanderthal extinction
(Golovanova et al., 2010), and many of these do not necessar-
ily involve changes in brain function and/or ability. Finally, while
recent studies indicate that Neanderthals were not as brutish as
once suspected (Rendu et al., 2013) many questions still remain
regarding the level of Neanderthal cognitive ability. In recent
years there has been an increasing number of reports that por-
tray Neanderthals as more culturally developed than had been
previously thought (Soressi et al., 2013).
In summary, given our limited knowledge in the above areas,
we cannot at present make conclusions regarding whether the
increased number of DUF1220 copies in Neanderthal conferred
any evolutionary advantage or disadvantage to that subspecies.
Nevertheless, the correlation betweenDUF1220 copy number and
brain size is retained even in this close human relative.
The evolutionary advantage of brain evolution being driven by
dosage increase
Of the potential genomic processes that could have produced the
evolutionarily rapid increase in neuron number among primates,
a mechanism involving copy number (dosage) increase would
offer a number of theoretical advantages. For example, if more
of a gene product conferred an evolutionary advantage, further
increasing copy number (dosage) would allow an increasingly
greater amount of product to be easily generated, presumably
delivering increasingly greater evolutionary benefit.
From this perspective, by relying on DUF1220 dosage increase
as the primary means of expanding neuron number, brain size,
and cognitive capacity, the primate order has fortuitously utilized
a unique mechanism that is highly expandable, i.e., it allows con-
tinued improvements to be generated simply by duplicating more
and more DUF1220 domains, i.e., increasing DUF1220 domain
dosage (Dumas and Sikela, 2009). In this scenario, evolutionary
variation in the DUF1220 sequence may not be as critical as vari-
ation in copy number. Also, it is noteworthy that a recent study
has reported that DUF1220 (i.e., the NBPF protein product) may
encoding a transcription factor (Zhou et al., 2013). If correct, this
finding suggests a plausible means by which an increase in dosage
could have a dramatic functional impact.
So why do other mammals with larger brains (elephants,
whales, e.g.,) not show the same progressively higher cognitive
capabilities as found in primates and particularly in humans?
The large increases in DUF1220 copy number are found only
among anthropoid primate species, and thus it is plausible that
evolutionary brain expansions in non-primate species have
occurred using genomic mechanisms other than the DUF1220
copy number increase utilized by primates (see Author Note).
In the event this is true, it could explain why the brains of these
other “intelligent” species have not approached or surpassed
the cognitive abilities of the human brain. In other words, non-
primate brain evolution did not use the same easily “expandable”
genomic mechanism for brain size increase, and instead used
ones that do not lend themselves to frequent and recurrent
expansions in brain size and cognition. Indeed, it has been
estimated that the types of large scale recombination events that
would produce copy number variations (CNVs) occur roughly
2–3 orders of magnitude more frequently than the types of point
mutations that might affect an alternative mechanism of gene
regulation (Itsara et al., 2010).
It should also be noted that a prediction of the above argument
is that, when measurements of neuron number become available
for large brained non-primates (elephants, cetaceans), the neu-
ron numbers will not be as extreme as those found in anthropoid
primates (and particularly human). In summary, increasing cog-
nitive capacity through increases in gene or domain copy number
provides a much more open-ended mechanism, allowing more
andmore cognitive enhancement by the relatively simple genomic
process of adding more and more copies (i.e., increasing dosage)
of the critical DNA sequences.
DUF1220 EVOLUTION AND GENOME ORGANIZATION
Human DUF1220 sequences are located in an evolutionarily
dynamic genomic region
The great majority of human DUF1220 sequences are located
in 1q21, one of the most evolutionarily dynamic regions of the
genome (Fortna et al., 2004; Popesco et al., 2006; O’Bleness et al.,
2012a). This region is adjacent to the human-specific C-band
at 1q12. C-bands have long been recognized as cytogenetically
visible chromosomal landmarks that are largely composed of het-
erochromatin and are polymorphic in the human population.
Three other human specific C-bands are found at 9q12, 16 and
Y, and these along with the one at 1q21.1 are adjacent to clus-
ters of genes that exhibit HLS increases in copy number in the
genome (Fortna et al., 2004; O’Bleness et al., 2012b). Interestingly,
the 1q21 region and flanking 1q12 region are positioned within a
HLS pericentromeric inversion that contains almost all of the 160
DUF1220 copies that were added specifically to the human lineage
since our split with the Pan lineages.
Selection has focused primarily on increasing the amount of
DUF1220 protein
DUF1220 is a protein domain of approximately 65 amino acids
and molecular analysis of DUF1220 coding sequences indicates
that DUF1220 domains show strong signatures of positive selec-
tion particularly among primates (Popesco et al., 2006). But it
is also clear that, among anthropoid species and particularly in
humans, evolution has primarily selected for more DUF1220
copies, many of which are virtually identical, rather than for a
highly diverged family.
This selection pressure on coding sequences notwithstanding,
it appears from the unprecedented increase in human copy num-
ber and the limited sequence divergence among human DUF1220
copies, that selection has primarily favored increasing the amount
of DUF1220 protein that can be produced (though such quan-
tifications are difficult to assess in practice, as they likely require
fetal brain tissue from each species). The importance of dosage
increase is further borne out by the observation that the HLS
DUF1220 triplet, which by adding approximately 148 DUF1220
copies to the human genome essentially doubled the number of
human DUF1220 copies, shows remarkably high sequence con-
servation (O’Bleness et al., 2012a). This suggests that in anthro-
poid species more copies of DUF1220 produce a greater dosage of
the DUF1220 protein domain, and that these products are acting
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to enhance or amplify a particular function. One such plausible
function would be to increase neuron number, which we have
previously mentioned closely parallels DUF1220 copy number
among primates.
Recent data has provided further evidence that selection pres-
sures have focused primarily on increasing DUF1220 dosage.
The number of DUF1220 domains encoded by each of the 20
human NBPF genes covers a broad range (from 5 to 67 copies)
(O’Bleness et al., 2012a). Surprisingly, rather than many differ-
ent sized proteins being produced (as would be expected from
the DUF1220 domain distribution in theNBPF gene family) only
a primary DUF1220 domain-including protein of 37 kDa is pro-
duced when evaluated by Western Blot (Popesco et al., 2006). In
theory, this product could accommodate 3–4 DUF1220 domains,
though its composition is still under investigation. Nevertheless,
this discovery suggests that this size-restricted protein product
may represent the major functional form of DUF1220 in human
brain and other tissues.
DUF1220 sequences are one of several core duplicons in the human
genome
A systematic genome-wide study showed that a select group of
sequences have undergone unusually rapid copy number expan-
sions in the human genome and, in so doing, have “dragged”
different flanking sequences along with them as they dupli-
cated and moved to new locations (Marques-Bonet and Eichler,
2009). These sequences have been termed “core duplicons” and
DUF1220 domains are the main core duplicon on chromosome 1.
While the DUF1220 copy number change fits with it being a core
duplicon, so does the location of DUF1220 sequences: they are
clustered but are inserted both in a tandem and an interspersed
manner.While such a configuration promotes genomic variability
and rapid evolutionary change, it also produces a highly disease-
prone genomic architecture (as described further in the next
section).
DUF1220 increase in humans has been accompanied by the
creation of a large disease burden
The greatest increase in DUF1220 copy number in humans has
occurred in the 1q21 region where approximately 240 of the
270 human DUF1220 sequences are located. The architecture
of this region is characterized by the presence of several NPBF
(DUF1220-encoding) genes that are typically interspersed by one
or more low copy number non-NBPF genes. In addition, each
NBPF gene encodes 5–60 DUF1220 domains tandemly arranged
on each gene. Thus, large numbers of DUF1220 copies are found
in this region in both interspersed and tandem arrangements.
Such an organization is an ideal genomic environment for recom-
bination events (e.g., NAHR) to occur, and these will often
involve low-copy, dosage-sensitive genes that flank NBPF genes
that undergo gains or losses in copy number due to the action of
DUF1220 core duplicons.
This prediction has been borne out by the discovery of a large
number of 1q21-CNVs that are disease-associated. At current
estimate, there are at least one dozen diseases that have been
reported that are associated with 1q21 CNVs, most of which
are immediately flanked by or encompass DUF1220 domains
(Dumas et al., 2012; O’Bleness et al., 2012b). Given the data
linking DUF1220 dosage increase to evolutionary adaptation (i.e.,
increase in brain size and cognitive ability), we have suggested
that this unusually large disease burden can be viewed as the price
that our species has paid, and continues to pay, for the rapid and
extreme evolutionary increase in DUF1220 copy number and for
the adaptive benefit this has conferred.
In support of this idea, we have developed a model that
proposes the following (Dumas and Sikela, 2009). Increased
DUF1220 copy number confers an evolutionary advantage that
is likely related to increases in brain size and cognitive ability.
Because the 1q21 region is very unstable, this increased the like-
lihood DUF1220 copy number would increase. Individuals who
exhibited the increased DUF1220 copy number would have a
selective advantage, which in turn would result in retention of
the 1q21.1 instability in these individuals. Thus, the evolution-
ary benefit of rapidly increasing DUF1220 copy number in the
human lineage resulted in favoring retention of the high genomic
instability of the 1q21.1 region. This in turn, has precipitated a
spectrum of recurrent human brain and developmental disorders,
including autism and schizophrenia.
Finally, DUF1220 sequences themselves are also thought to be
major contributors to the current instability of the 1q21 region.
Interspersed among the 53 genes in the 1q21.1 region are more
than a dozenNBPF genes that together encode approximately 240
DUF1220 domains. Such a duplication-rich genome architecture
provides the potential for numerous different recombination sce-
narios that could be mediated by DUF1220 sequences that would
result in gain or loss of the many intervening non-NBPF genes
in the region. Thus, given the often deleterious consequences of
these types of rearrangements, it is not surprising CNVs in this
region have already been linked to somany phenotypically diverse
disorders (Dumas et al., 2012).
DUF1220 DOSAGE IS LINKED TO BRAIN SIZE DIFFERENCES WITHIN THE
HUMAN SPECIES
DUF1220 copy number and microcephaly and macrocephaly
Multiple independent reports have shown that deletions and
duplications in 1q21 are associated with microcephaly and
macrocephaly, respectively (Brunetti-Pierri et al., 2008; Mefford
et al., 2008). These findings strongly suggest that the copy number
of one or more sequences in this region is directly influenc-
ing human brain size. These CNVs, while containing a number
of non-DUF1220 encoding genes, also either encompass or are
immediately flanked by DUF1220 domains (Dumas and Sikela,
2009). Recently we used specialized DNA micro-arrays covering
the 1q21 region for an arrayCGH analysis of 42 individuals with
microcephaly or macrocephaly, that had been previously shown
to contain 1q21 deletions or duplications. In this study, DUF1220
copy number exhibited the highest consistent correlation with
head circumference among all 1q21 genes that were examined
(N = 53) (Dumas et al., 2012).
Finally, of the genes in the 1q21.1 CNVs where dosage has been
linked with brain size, only those encoding DUF1220 domains
show such an extreme HLS evolutionary change (O’Bleness et al.,
2012a) that also parallels brain size increase among anthropoid
species (monkeys, apes, human).
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DUF1220 dosage is associated with brain gray matter volume in a
non-disease population
To investigate whether DUF1220 copy number influences brain
size in a non-disease population, arrayCGHwas carried out using
DNA from 59 otherwise normal individuals for which brain MRI
profiles had been obtained. Results from non-disease individu-
als at the two extremes of gray matter volume (as determined
by MRI), indicate that the large brain group had more DUF1220
copies than the small brain group (CON1 p = 0.0246 and CON2,
p = 0.0134). No other genes in the 1q21 region (N = 53) showed
the consistent correlation between brain size and copy number
found for DUF1220-related sequences among these non-disease
and disease (1q21-associated microcephaly and macrocephaly)
populations. Finally no genes in the 1q21 region, or for that
matter anywhere else in the genome, show the extreme human
copy number expansion observed for DUF1220 domains that also
closely parallels increases in primate brain size (Dumas et al.,
2012).
DUF1220 copy number, autism, and schizophrenia
It has been proposed that autism and schizophrenia may be oppo-
site extremes of the same cognitive pathology (Crespi, 2013). This
model is supported in part by studies of disease-related CNVs in
which deletions are associated with one condition while recipro-
cal duplications are associated with the other condition. Of par-
ticular relevance here is the finding that 1q21 duplications have
been associated with autism while reciprocal 1q21 deletions have
been associated with schizophrenia (Crespi, 2013). As we noted
earlier, these CNVs either encompass or are flanked by numer-
ous DUF1220 domain sequences (Dumas and Sikela, 2009). In
addition, individuals with autism tend to have larger than aver-
age brains or specific brain regions (reviewed in Corchesne et al.,
2007), while individuals with schizophrenia tend to have smaller
than normal brains (Haijma et al., 2013), suggesting that the
dosage of key gene-related sequences that underlie these disor-
ders may also play a role in influencing brain size. It terms of 1q21
genes, we have recently shown that of 53 genes that map to 1q21,
DUF1220-related sequences show the most consistent correla-
tion with brain size among both normal and disease-associated
populations (Dumas et al., 2012). Such findings provide further
support to the notion that DUF1220 may be linked to autism and
schizophrenia.
It has also been suggested that the same key genes that
have been important to human-specific brain evolution will be
shown to also underlie schizophrenia (Crow, 1995), a possibil-
ity that fits with what we know about DUF1220 domains being
important to human evolution. More recently we have found
a more direct link between DUF1220 and ASD. Namely that,
in individuals with ASD, DUF1220 subtype CON1 is linearly
associated, in a dose response manner, with increased sever-
ity of each of the three primary symptoms of ASD: increased
social deficits (p = 0.021), increased communicative impair-
ments (p = 0.030), and increased repetitive behaviors (p =
0.047) (Davis et al., 2014). Finally, it is worth noting that
DUF1220 copy number in the human population is highly poly-
morphic (for example, copy number of the DUF1220 CON1
subtype ranges from 56 to 88 and follows a Gaussian curve)
(Davis et al., 2014). This feature implies that the DUF1220 fam-
ily, by itself, provides a rich source of functional allelic variation
and as such has the capacity to produce a broad continuum
of phenotypic effect. While these findings support a poten-
tial role for DUF1220 in autism and schizophrenia, a more
detailed discussion of this possibility is being presented else-
where.
MODELS OF HOW DUF1220 DOMAIN DOSAGE COULD BE
DRIVING NEURON NUMBER AND BRAIN SIZE
The data presented above suggest a possible role for DUF1220
dosage in influencing neuron number in the primate brain. There
are several plausible mechanisms through which this may be
brought about and these are described in the following section.
DUF1220 AND THE CENTROSOMAL EFFECT ON BRAIN SIZE
Virtually all genes that have been implicated in primary micro-
cephaly encode proteins that function at the centrosome, a fact
that has led to the suggestion that genes that act at the centro-
some may play key roles in the regulation of brain size (Thornton
and Woods, 2009). In light of this, it is noteworthy that the
ancestral DUF1220 domain is encoded by a large gene, phos-
phodiesterase family member 4D interacting protein (PDE4DIP
or myomegalin), that is also expressed at the centrosome (Verde
et al., 2001). Interestingly, one of the genes implicated in micro-
cephaly, CDK5RAP2, is also a homolog of PDE4DIP but lacks
a DUF1220 domain (Cox et al., 2006). While these observations
place the ancestral form of DUF1220 at the centrosome, and are
consistent with the possibility that DUF1220 may be involved in
centrosomal functions related to brain size, these findings should
be viewed as suggestive and additional follow up investigations
are needed.
In mice, the earliest progenitor cells (neuroepithelial cells)
have an attachment to the apical surface. Early divisions bisect
this attachment such that each daughter cell receives apical
attachment proteins, remains attached to the apical surface, and
(possibly because of this attachment) retains the neuroepithelial
identity. This division is called a symmetrical proliferative divi-
sion. Later in development, asymmetric divisions leave only one
daughter cell attached to the apical surface. The cell that is no
longer attached will migrate basally and become either a basal
progenitor or a neuron. The number of rounds of symmetric cell
divisions that occur before cells begin to divide asymmetrically
is therefore a determinant in the final number of neurons, and
this timing of when this switch occurs can have extreme effects
on neuron number. Because DUF1220 expression in brain is
restricted to neurons (Popesco et al., 2006), this may also explain
why these scaling rules do not appear to apply to glial cells, even
though they are derived from the same progenitor population.
For example, it has been pointed out that 10 rounds of asym-
metric cell division by one progenitor would produce 10 neurons.
However, if all but the last round of cell division are symmetric,
one progenitor will produce 512 neurons (Thornton and Woods,
2009). The type of cell division (symmetric vs. asymmetric) is
thought to be controlled by the orientation of the centrosomes
within the cell. The association between DUF1220 and brain size
therefore suggests that the PDE4DIP, which is expressed at the
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centrosome and contains a DUF1220 domain, may play a role in
this orientation.
THE PRIMARY CILIA AS A BALANCE BETWEEN PROLIFERATION AND
CELL DENSITY-DEPENDENT DIFFERENTIATION
Primary cilia are sensory structures long thought to be the bal-
ance between further progression through the cell cycle and cell
cycle exit. An effect on this structure might therefore be an ideal
place to both sense local cell density and drive additional rounds
of proliferation.
Vandepoele et al. showed that the NBPF1 protein, which has
seven DUF1220 domains, directly interacts with a protein called
chibby (Vandepoele et al., 2010). Chibby is known to be involved
in two cellular processes. The first is as a negative regulator of the
Wnt/beta catenin pathway, wherein chibby is capable of migrat-
ing into the nucleus, binding beta catenin, and escorting it out
of the nucleus, thereby preventing beta catenin-mediated tran-
scription from occurring (Takemaru et al., 2003; Li et al., 2008).
The second function ascribed to chibby occurs at the centri-
ole, where it acts as a scaffold upon which the primary cilium
is built. When a TOPFLASH assay was performed to investigate
whether addition of NBPF1 had any effect on Wnt/beta catenin
signaling in DLD1 cells in culture, no change between NBPF1
and mock induced cells was found. It is therefore possible that
the nature of the NBPF1/chibby interaction is to influence pri-
mary cilia generation, which could affect the cell cycle. This
would be consistent with the discovery that many NBPF genes
contain an EVI5 promoter that was duplicated from the unre-
lated EVI5 gene that is known to encode a centrosomal protein
(Vandepoele et al., 2009).
Primary cilia are well conserved structures, present in almost
every mammalian cell type (Anderson et al., 2008). They are non-
motile, sensory organelles, built during G1 of the cell cycle and
mark the exit from the cell cycle, into G0. Conversely, resorp-
tion of the primary cilia is associated with reentry into the cell
cycle (Plotnikova et al., 2009). This may be true because the cen-
trioles nucleate both the primary cilium and the centrosome,
which is necessary for mitosis. In this model, the centriole there-
fore functions as a fulcrum upon which exit from the cell cycle is
determined.
Chibby is known to localize to the distal end of the mother
centriole, upon which a primary cilium is built, and it is essen-
tial for primary cilium construction (Steere et al., 2012). It
follows then that a protein capable of binding to chibby and
preventing its use as a structural support during primary cilia
generation would prevent the cell from exiting the cell cycle,
and therefore force extra rounds of cell division. The known
DUF1220 interaction with chibby therefore provides a plausible
means by which extra rounds of neuronal cell divisions could be
accomplished.
Circumstantial support can be found in many ependymomas,
which are tumors of the ependymal cells that line the ventricles of
the brain in adults (the cells that radial glia ultimately differenti-
ate into). Interestingly, the twomost common genetic aberrations
found in these diseases are a gain of chromosome 1q (where most
of the DUF1220 domains map) (Mendrzyk et al., 2006) or a loss
of chibby (Karakoula et al., 2008).
NEOTENY
Heterochrony is any difference between a species and its ances-
tral form in the timing or duration of developmental events,
such as neural progenitor proliferation. Neoteny occurs when
the developmental window in the extant species is lengthened.
In the absence of available data regarding rates of development
in ancestral forms, extant species are frequently used instead.
Indeed, it has been observed that the window of brain devel-
opment has been extended from mouse to macaque, and from
macaque to human (Kornack and Rakic, 1998), and this pattern
is thought to extend to many other primate species (see http://
bioinformatics.ualr.edu/ttime/home.php). In a primate model
of brain development that emphasizes neuron number per unit
time, rather than accumulation of cell mass, such a protracted
window of neural development makes intuitive sense: more time
spent in this stage may generate more neurons, and thus a
bigger brain. Drawing out the window of development during
which neural progenitor cells are generated, therefore, is a plau-
sible mechanism by which DUF1220 may be influencing neural
development.
Also it is worth mentioning that DUF1220 is expressed in sev-
eral human tissues in addition to brain (Popesco et al., 2006), and
there are several organs along with brain that exhibit neotenous
developmental patterns in human.
A second, less obvious possibility is that the extra time humans
spend in the window of neural development preserves the long
distance connectivity important for higher cognitive function and
changes in this timing may underlie some forms of cognitive dis-
ease. The human brain develops in an “inside out” pattern, with
each wave of dividing neurons migrating past their predecessors
and taking up residence basally to those cells. For normal brain
connectivity, each wave most likely requires a certain amount of
time to migrate to the appropriate location in the cortical plate
and project its neurites outward. If cell division occurs too quickly
and the next wave of dividing neurons is immediately behind
the former, the developing cortex will get crowded very quickly.
These cells will most likely not have enough time to send out neu-
rites before being physically blocked by the next wave of neurons
settling on top of them—particularly long distance projection
axons.
This inability to form long distance projection neurons may
therefore lead to an overly localized connectivity pattern, a
brain related condition that has been associated with autism
(Corchesne et al., 2007). The combination of not only how many
neurons are made, but also how fast they are made, may therefore
explain why greater than average brain growth in early postnatal
years is associated with autism, and offers a potential explanation
of why DUF1220 copy number increase can be associated with
both macrocephaly (Dumas et al., 2012) and autism (Davis et al.,
2014).
ALTERNATIVE MODELS
With the increasing availability of primate genome sequences, the
identification of genes, and other genomic variations that show
HLS changes has accelerated (for a recent review see O’Bleness
et al., 2012b), and a number of these have been potentially linked
to human brain evolution.
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MICROCEPHALY GENES
As mentioned previously (section DUF1220 and the Centrosomal
Effect on Brain Size), several genes have been identified that
when mutated lead to autosomal recessive primary microcephaly
including ASPM, microcephalin (MCPH), and CDK5RAP2
(Megraw et al., 2011). It is noteworthy that these all appear to
encode proteins that are found at the centrosome, a feature has led
to the suggestion that brain size may be influenced by genes that
control centrosomal function. While some studies have shown
that the ASPM gene coding region is under positive selection,
this observation was not confirmed by a subsequent independent
investigation and thus there remains some uncertainty about how
involved these genes are in brain evolution.
HAR1F
The human accelerated region 1F (HAR1F) gene was identified
from a genome-wide search for genes that had undergone the
most extreme human-specific sequence changes (Pollard et al.,
2006). Though the precise function of HAR1F is unknown, it
encodes an RNA product and is expressed at high levels in the
fetal brain. While HAR1F shows a dramatic sequence divergence
specifically in humans, the sequences do not change significantly
in other mammalian (or primate) species, making it unlikely that
it is responsible for primate brain expansion.
Additional work on human accelerated sequences has been
carried out and a number of these may function as developmen-
tal enhancers (Capra et al., 2013). Also the NPAS3 gene, which
is thought to encode a transcription factor, has been shown to
contain a high number of human accelerated elements (Kamm
et al., 2013a,b). Such rapidly evolving genomic sequences may
have contributed to the evolution of human-specific traits and
warrant further investigation.
SRGAP2
The SRGAP2 gene, encoding a Slit-Robo GTPase, was reported
to have undergone a human specific duplication that blocked the
normal inhibitory domain of SRGAP2, resulting in an enhance-
ment in its function (Dennis et al., 2012). Because SRGAP2 has
been associated with neuronal migration, it has been suggested
that this event may have produced an enhancement of this ability
in the human brain. While it is possible that SRGAP2 may have
contributed to recent human brain evolution, outside of humans
it does not change in copy number to any appreciable degree
(Dumas et al., 2012) and thus does not show the strong paral-
lels between copy number increase and primate brain expansion
as seen with DUF1220 domains.
However, it is worth mentioning that recent data has raised
the possibility that some key brain-related gene changes may have
been simultaneous. For example, the SRGAP2 duplication that
has been proposed to have contributed to human brain evolu-
tion by effecting neuronal migration, is very near two NBPF (i.e.,
DUF1220 encoding) genes on chromosome 1 that also duplicated.
Given DUF1220’s role as a core duplicon that promotes duplica-
tion of other nearby sequences, it is possible that the SRGAP2
duplication was due to recombination events that were medi-
ated by DUF1220 sequences. Should this be confirmed, it would
imply that the SRGAP2 duplication and the duplication of the
nearby NBPF genes, that added approximately 20 more copies of
DUF1220 to the human genome, may have occurred as part of the
same duplicative transposition event, i.e., at the same time and
within the past 2 million years. It is plausible that such an instan-
taneous change, involving two potentially complementary brain
processes (neuronal migration and neuron number), could have
had a major sudden beneficial impact on human brain function.
GENE EXPRESSION
It has been suggested that changes in the regulation of genes,
that alter their spatial and/or temporal expression, could be
important to human evolution. While this view was based on
minimal knowledge of the human and chimp genomes, the con-
cept that gene regulation is important to evolutionary change
remains a valid hypothesis and has been investigated using the
latest genomic tools (Johnson et al., 2009). Also, modifications
in enhancer sequences may be potential contributors to human
brain evolution. The importance of such sequences in forelimb
evolution has been reported, though not directly related to brain-
related changes. Many other non-coding regions could in theory
be contributors to the evolution of the primate brain, though
testing of such candidate sequences is currently challenging.
Regardingmechanisms that could contribute to enhanced cog-
nition, the data described earlier supports the view that the
expansion of the primate brain, and the parallel increase in cogni-
tive capacity, may be largely due to an increase in neuron number.
While it is theoretically possible that changes in neurons, alone,
are sufficient to lead to enhanced cognition, there may be other
brain-related changes, e.g., involving glial cells, which also con-
tribute. This possibility has been given recent support by the find-
ing that transplanting human glia into a mouse brain is sufficient
to lead to enhanced learning in a mouse (Han et al., 2013).
While the above genes and mechanisms show relevance to
human brain size and/or evolution, none exhibit the striking
changes across primate lineages that is seen with DUF1220 copy
number and that parallels the increases in brain size found
among these species. In addition, gene duplication (or domain
duplication in the case of DUF1220) has long been recognized as
a major mechanism underlying evolutionary change, and further
that extremely duplicated sequences underlie extreme biological
change (Rouquier et al., 2000). Given these observations, the fact
that DUF1220 shows the largest number of HLS duplications
(approximately 160 copies) of any protein coding region in
the genome provides strong support that these sequences are
major contributors to human-specific evolutionary change. In
summary, we believe that after the above alternative theories and
candidates are examined, none are comparable to the DUF1220
model in its ability to readily account for the progressive expan-
sion of the primate brain as one moves from monkeys to apes to
humans.
REMAINING QUESTIONS
TISSUE AND DEVELOPMENTAL EXPRESSION
Immunocytochemistry studies of postmortem human brain indi-
cate that, in adult human brain, DUF1220 protein expression is
restricted to neurons (cell bodies and dendrites) and it is abun-
dantly expressed in the neocortex, thought to be important in
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higher cognitive functions. However, DUF1220 protein is also
expressed in several other human tissues (Popesco et al., 2006).
If DUF1220 dosage is contributing to an increase in brain size,
it is unclear what function it may have in other tissues in which
it is also expressed. One possibility is that DUF1220 is involved
in neoteny which as discussed earlier is thought to involve other
developmental processes in addition to those related to brain If
DUF1220 is having a proliferative effect that acts to enforce ear-
lier cell division in the cell cycle at the expense of longer growth
phases (therefore stimulating larger numbers of smaller cells),
then onemight expect the same trend seen in the primate brain to
occur in other tissues in which DUF1220 is expressed, i.e., smaller
cells but in greater numbers. Data for other organs in which
DUF1220 is expressed does not yet exist to rigorously evaluate
this hypothesis.
Also if DUF1220 is functioning to increase brain neuron num-
ber it can be expected that it will be expressed at developmental
stages during which brain neurogenesis is particularly active.
Investigation of this possibility is currently underway (see Author
Note).
DUF1220 DOMAIN PROTEINS: STRUCTURE AND FUNCTION
There are approximately 23 different DUF1220-encoding genes
(NBPF) and they are predicted to encode a wide spectrum of dif-
ferent sized protein products. However, this is not the case and the
primary HLS DUF1220-encoding protein that is detected in brain
and other tissues is a single product of approximately 37 kDa. This
may indicate that DUF1220 domains are processed (either post-
transcriptionally or post-translationally) or possibly translated
from unique internal initiation sites, in such a way that a 37 kDA
protein product is consistently produced. Whether this product
represents a specific form (e.g., an active or inactive form) or the
only form is currently unknown. How this single protein product
is generated and what function(s) it performs are topics currently
under investigation.
BENEFITS AND LIMITATIONS OF MODELING DUF1220 FUNCTION IN
ANIMAL MODELS
The use of transgenic mouse models to study gene function
in vivo has had widespread utility, and these studies are cur-
rently underway in DUF1220 transgenic mice. However, while
mice have one copy of DUF1220 in their genome, it is only
the ancestral form (i.e., found in the PDE4DIP gene); they do
not have the form that has increased in primates (i.e., the type
encoded by the NBPF family). The primate form of DUF1220
was generated when the ancestral DUF1220 domain underwent
a duplicative transposition, in which the DUF1220 copy in the
PDE4DIP gene duplicated and the new copy inserted into a com-
pletely different genomic environment (O’Bleness et al., 2012a).
This then became the NBPF-type DUF1220 family that greatly
expanded in primates and has diverged considerably from the
ancestral form. Mice have noNBPF genes and therefore no copies
of DUF1220 outside of the one that is part of the PDE4DIP gene.
While it is certainly possible that human DUF1220 copies will
function normally when placed in the mouse genome, it is also
possible that they may not function as they would when in the
human (or any other primate) genome because the appropriate
genomic environment is lacking in mouse. While these con-
cerns are specific to “humanized” DUF1220 mice, an alternative
approach is to remove the single DUF1220 domain in the mouse
genome. Such DUF1220 KO mice have been generated, are viable
and are currently under study. These represent the first animal
model of DUF1220 function and should provide insight into the
role of the ancestral DUF1220 domain.
CONCLUSIONS
All the above data taken together point to a hypothesis regarding
the evolutionary expansion of the anthropoid brain: Dosage of
DUF1220 protein domains underlies the unique neuronal scaling
rules seen in primates. Specifically, increases in DUF1220 dosage
cause an increase in neuron number, resulting in a larger brain
and greater cognitive ability. Whether the relatively consistent
maintenance of cell size observed uniquely in primates is caused
by DUF1220, and this is driving progenitor cell division, or if
rapid cell division is causing neural cells to be smaller by spend-
ing less time in growth phases is not clear. Alternatively, it is also
possible that neuronal cell size and density are not being held
constant by DUF1220, but are simply not actively being modi-
fied by whatever other process affects brain size in non-primate
mammals.
In summary, the remarkable increase in the copy number of
sequences encoding DUF1220 protein domains in anthropoid
species and particularly human, suggests that there were strong
evolutionary selection pressures at work driving this expansion.
Here we present data that suggests that the benefits accrued to
the anthropoid lineages by virtue of increasing DUF1220 dosage
were primarily related to brain evolution and cognitive capacity.
Validation of this testable hypothesis awaits further investigation
into the function of DUF1220 domains. In this regard, the model
does make a number of testable predictions including (1) the
unique brain evolution mechanism that appears to be unique to
primates will be found to be manifest in the anthropoid lineages
and will not evident in prosimians, (2) DUF1220 copy num-
ber will be linked to cognitive aptitude measures in the human
population, and (3) DUF1220 will be shown to influence neu-
ron number and/or processes that involve brain development and
expansion among anthropoid primates.
While this hypothesis proposes that DUF1220 dosage is a key
driver of primate brain evolution, it appears to have come at a
very high cost. As mentioned earlier, DUF1220 sequences have
undergone an unusually rapid and extreme increase in copy num-
ber in the 1q21 region. However this process has unfortunately
also produced a highly disease-prone genome architecture for that
region. For example, to date there have been at least a dozen
different human diseases, including autism and schizophrenia,
that have been linked to 1q21-associated CNVs (Dumas et al.,
2012). In other words, many individuals receive highly delete-
rious versions of the 1q21 region of our genome as a result
of the disease-prone, though evolutionarily adaptive, genome
architecture of this region which has been largely shaped by
DUF1220-related events. When viewed in this manner, this is the
severe price that has been and continues to be paid for the large
number of DUF1220 copies we have, and for our unusually large
brain size and neuron number and exceptional cognitive capacity
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(Dumas and Sikela, 2009). One may hope that appreciation for
how this process works will lead to much greater compassion
for those who, through no choice of their own, are forced to
carry this severe disease burden, while we fortunate ones are the
beneficiaries of this same evolutionary process.
AUTHOR NOTE
Since this work was completed and submitted two reports
appeared that provide additional support for the hypotheses
presented here. First, transfection of DUF1220 sequences has
been shown to promote proliferation of human neural stem
cells (H9-derived) providing direct evidence in support of the
view that DUF1220 may function by increasing neuron number
(Keeney et al., in press). In addition, in situ hybridization analy-
ses across human fetal brain development, shows that DUF1220
domains are expressed in the ventricular zone and primarily dur-
ing human cortical neurogenesis, and therefore are expressed at
the right time and place to be affecting cortical brain develop-
ment. Second, it has been demonstrated that dolphins, a non-
primate mammal with a relatively large brain and high cognitive
capacity but low DUF1220 copy number, show unusually strong
selection on the protein coding regions of genes previously impli-
cated in human brain function and psychiatric disorders, while
other species including humans do not show such coding region
selection (Ogawa and Vallender, 2014). These results suggest that
dolphin (cetacean) brain evolution may have taken a path distinct
from that utilized in the primate order and are consistent with the
hypothesis that primate brain evolution may have primarily uti-
lized a unique genetic mechanism, DUF1220 dosage increase, to
facilitate brain expansion.
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